Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

• Published in: Journal of headache and pain Vol. 24; no. 1; pp. 59 - 11
• Main Authors: Straube, Andreas, Broessner, Gregor, Gaul, Charly, Hamann, Xenia, Hipp, Joachim, Kraya, Torsten, Neeb, Lars
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 23.05.2023; Springer Nature B.V; BMC
• Subjects: Antibodies, Monoclonal; Calcitonin gene-related peptide; Fremanezumab; Headache; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine; Migraine Disorders; Monoclonal antibodies; Neurology; Non-responder; Pain Medicine; Patients; Pharmacovigilance; Prospective Studies; Calcitonin gene-related peptide; Fremanezumab; Non-responder; Migraine

Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This...